Arjuna to Present Data on Ag5 and the TMC platform at AACR Annual Meeting 2021

March 24, 2021 - PRLog -- London, Santiago de Compostela
ARJUNA Therapeutics announced today that data for Arjuna's preclinical Ag5 program will
be presented at the American Association of Cancer Research (AACR) 2021 Annual Meeting.

Abstract # 2020: Derived from a platform of innovative therapeutic molecular clusters
(TMC), Ag5 is a highly potent and differentiated molecule that promises to be efficacious in
hard-to-treat solid cancers.
Poster: April 10, 2021 8:30 AM-11:59 AM EST, Session PO.MCB11.01 - Cellular Stress
Responses

The poster shows Ag5 being a highly potent pan-cancer therapeutic selectively targeting
high ROS expressing cancer cells in what can be classified as metabolic synthetic lethality.
Specifically, based on its unique and novel catalytic activity, it targets redundant antioxidant
systems which are typically expressed in mitochondria and commits cancer cells to
programmed cell death. In addition, expression of oncogenic drivers such as KRAS is
correlated with increased ROS levels and thereby sensitizes cells to Ag5. Consequently,
combination treatment with a KRAS G12C inhibitor resulted in enhanced cell killing over Ag5
monotherapy efficacy in cell lines carrying the G12C mutation. Also, Ag5 has demonstrated
anti-tumor efficacy in orthotopic cancer models, and due to its very small size has been
shown to cross the blood-brain-barrier. Several preclinical studies did not show any toxicity
of Ag5 dosing.

"We are pleased to describe the unique metabolic synthetic lethality mechanism of action
of our lead drug Ag5 for the first time. Our data shows that this drug has the potential to
treat cancers that generate high levels of reactive oxygen species, a group which makes up
over a third of all cancers and which up to now has had no effective treatment," said Martin
Treder, Ph.D., CSO of ARJUNA. "We are particularly excited that Ag5 demonstrated high
potency in vitro and in vivo, while at the same time being safe in preclinical models, thus
offering the promise of an effective therapy without significant side effects."

ARJUNA Therapeutics is developing an entirely novel platform of orally available small
molecules to address the unmet needs in cancer medicine. The first molecule in ARJUNA's
pipeline, Ag5, is a pan-tumour targeted therapy that crosses the blood-brain-barrier
directed at tumours with mitochondrial dysfunction - a very large group of untreatable
cancers characterized by KRAS mutations or other biomarkers, and glioblastoma
multiforme.

For more information, visit our website:
http://arjunatherapeutics.com